Founder von Willebrand factor haplotype associated with type 1 von Willebrand disease

被引:75
|
作者
O'Brien, LA
James, PD
Othman, M
Berber, E
Cameron, C
Notley, CRP
Hegadorn, CA
Sutherland, JJ
Hough, C
Rivard, GE
O'Shaunessey, D
Lillicarp, D [1 ]
机构
[1] Queens Univ, Dept Pathol, Richardson Lab, Kingston, ON K7L 5L9, Canada
[2] Queens Univ, Dept Chem, Kingston, ON K7L 5L9, Canada
[3] Hop St Justine, Dept Hematol, Montreal, PQ H3T 1C5, Canada
[4] Univ Southampton, Dept Haematol, Southampton SO9 5NH, Hants, England
关键词
D O I
10.1182/blood-2002-12-3693
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
To date, no dominant mutation has been identified in a significant proportion of patients with type 1 von Willebrand disease (VWD). In this study, we examined 70 families as part of the Canadian Type 1 VWD Study. The entire VWF gene was sequenced for 1 index case, revealing 2 sequence variations: intron 30 (5312-19A>C) and exon 28 at Tyr1584Cys (4751A>G). The Tyr1584Cys variation was identified in 14.3% (10 of 70) of the families and was in phase with the 5312-19A>C variation in 7 (10.0%) families. Both variants were observed in 2 of 10 UK families with type 1 VWD, but neither variant was found in 200 and 100 healthy, unrelated persons, respectively. Mean von Willebrand factor antigen (VWF:Ag), VWF ristocetin cofactor (VWF:RCo), and factor VIII coagulant activity (FVIII:C) for the index cases in these families are 0.4 U/mL, 0.36 U/mL, and 0.54 U/mL, respectively, and VWF multimer patterns show no qualitative abnormalities. Aberrant VWF splicing was not observed in these patients, and both alleles of the VWF gene are expressed as RNA. Molecular dynamic simulation was performed on a homology model of the VWF-A2 domain containing the Tyr1584Cys mutation. This showed that no significant structural changes occur as a result of the substitution but that a new solvent-exposed reactive thiol group is apparent. Expression studies revealed that the Tyr1584Cys mutation results in increased intracellular retention of the VWF protein. We demonstrate that all the families with the Tyr1584Cys mutation share a common, evolved VWF haplotype, suggesting that this mutation is ancient. This is the first report of a mutation that segregates in a significant proportion of patients with type 1 VWD. (C) 2003 by The American Society of Hematology.
引用
收藏
页码:549 / 557
页数:9
相关论文
共 50 条
  • [1] Changes in von Willebrand factor level and von Willebrand activity with age in type 1 von Willebrand disease
    Rydz, N.
    Grabell, J.
    Lillicrap, D.
    James, P. D.
    [J]. HAEMOPHILIA, 2015, 21 (05) : 636 - 641
  • [2] Changes in von Willebrand factor level and von Willebrand activity with age in type 1 von Willebrand disease
    Rydz, N.
    Grabell, J.
    Lillicrap, D.
    James, P.
    [J]. HAEMOPHILIA, 2012, 18 : 198 - 198
  • [3] von Willebrand disease and von Willebrand factor
    Sadler, Brooke
    Castaman, Giancarlo
    O'Donnell, James S.
    [J]. HAEMOPHILIA, 2022, 28 : 11 - 17
  • [4] von Willebrand Factor and von Willebrand Disease
    王兆钺
    [J]. 血栓与止血学, 2005, (04) : 147 - 149
  • [5] Detection of type 1 von Willebrand Disease with increased von Willebrand Factor clearance
    Meiring, M.
    Setlaba, P.
    Coetzee, M.
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 : 1147 - 1147
  • [6] von Willebrand factor alloantibodies in type 3 von Willebrand disease
    Kotnik, Barbara Faganel
    Strandberg, Karin
    Debeljak, Marusa
    Kitanovski, Lidija
    Jazbec, Janez
    Benedik-Dolnicar, Majda
    Bakija, Alenka Trampus
    [J]. BLOOD COAGULATION & FIBRINOLYSIS, 2020, 31 (01) : 77 - 79
  • [7] Increase of von Willebrand factor with aging in type 1 von Willebrand disease: fact or fiction?
    Borghi, Mariachiara
    Guglielmini, Giuseppe
    Mezzasoma, Anna Maria
    Falcinelli, Emanuela
    Bury, Loredana
    Malvestiti, Marco
    Gresele, Paolo
    [J]. HAEMATOLOGICA, 2017, 102 (11) : E431 - E433
  • [8] Von Willebrand factor and von Willebrand disease - Preface
    Michiels, JJ
    [J]. BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2001, 14 (02) : VII - VII
  • [9] Von Willebrand factor inhibitors developed in type 3 von Willebrand disease
    Megdiche, F.
    Kassar, O.
    Hdiji, S.
    Mbarek, L.
    Charfi, M.
    Elloumi, M.
    Kallel, C.
    [J]. HAEMOPHILIA, 2019, 25 : 87 - 87
  • [10] Reduced von Willebrand factor survival in type Vicenza von Willebrand disease
    Casonato, A
    Pontara, E
    Sartorello, F
    Cattini, MG
    Sartori, MT
    Padrini, R
    Girolami, A
    [J]. BLOOD, 2002, 99 (01) : 180 - 184